How important is HER2/neu amplification and expression when selecting patients for HER2/neu-targeted therapies?

Clinical Breast Cancer

Volumn 5, Issue 1, 2004, Pages 70-71

  Davol, Pamela A ^a   Lum, Lawrence G ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CLINICAL TRIAL; COMPUTER PROGRAM; CORRELATION ANALYSIS; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DRUG RESPONSE; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY TEST; PATIENT SELECTION; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SCANNING ELECTRON MICROSCOPY; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; TISSUE FIXATION; TREATMENT OUTCOME;

EID: 3042624853     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-8209(11)70837-0     Document Type: Note

References (19)

1. Gancberg D, Jarvinen T, di Leo A, et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 2002; 74:113-120.
2. Werner M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000; 24:1016-1019.
3. Montero C. The antigen-antibody reaction in immunohistochemistry. J Histochem Cytochem 2003; 51:1-4.
4. Epstein RJ. Preferential detection of catalytically inactive c-erbC-2 by antibodies to unphosphorylated peptides to mimicking receptor tyrosine autophosphorylation sites. Oncogene 1995; 11:315-323.
5. Owens MA, Horten BC, Da Silva MM, et al. HER2 amplification ratios by fluorescence in situ hybridization with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5:63-69.
6. Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 20021; 88:1587-1591.
7. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 2001; 92:2965-2974.
8. Carraway KL, 3rd, Cantley LC. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signalling. Cell 1994; 78:5-8.
9. Carraway KL, 3rd, Soltoff SP, Diamonti AJ, et al. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem 1995; 270:7111-7116.
10. Culouscou JM, Plowman GD, Carlton GW, et al. Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor. J Biol Chem 1993; 268:18407-18410.
11. Gilmore AP, Valentijn AJ, Wang P, et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002; 277:27643-27650.
12. Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling a pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 2002; 80:231-238.
13. Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000; 18:3230-3239.
14. Thor A. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? J Natl Cancer Inst 2001; 93:1120-1121.
15. Davol PA, Bagdasaryan R, Elfenbein GJ, et al. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res 2003;63:6772-6783.
16. Davol P, Beitz JG, Frackelton AR, Jr. Autocrine down regulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line. J Invest Dermatol 1995; 104:916-921.
17. Lum LG, Rathore R, Cummings F, et al. Phase I/II study of treatment of stage IV breast cancer with OKJT3 x trastuzumabarmed activated T cells. Clin Breast Cancer 2003; 4:212-217.
18. Fornier M, Seidman AD, Esteva FJ, et al. Weekly (W) Herceptin (H) + 1 hour Taxol (T): Phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999; 18:126a (Abstract #482).
19. Bell R. Ongoing trial with trastuzumab in metastatic breast cancer (review). Ann Oncol 2001; 12(suppl):S69-S73.